Citius Pharmaceuticals (47N0) Price & Analysis

Q: What was Citius Pharmaceuticals’s price range in the past 12 months?

Citius Pharmaceuticals lowest stock price was €3.29 and its highest was €3.29 in the past 12 months.

Q: What is Citius Pharmaceuticals’s market cap?

Citius Pharmaceuticals’s market cap is €13.88M.

Q: When is Citius Pharmaceuticals’s upcoming earnings report date?

Citius Pharmaceuticals’s upcoming earnings report date is Dec 17, 2026 which is in 102 days.

Q: How were Citius Pharmaceuticals’s earnings last quarter?

Citius Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -€0.294 earnings per share for the quarter, beating the consensus estimate of -€0.311 by €0.017.

Q: Is Citius Pharmaceuticals overvalued?

According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Citius Pharmaceuticals pay dividends?

Citius Pharmaceuticals does not currently pay dividends.

Q: What is Citius Pharmaceuticals’s EPS estimate?

Citius Pharmaceuticals’s EPS estimate is -0.35.

Q: How many shares outstanding does Citius Pharmaceuticals have?

Citius Pharmaceuticals has 27,452,570 shares outstanding.

Q: What happened to Citius Pharmaceuticals’s price movement after its last earnings report?

Citius Pharmaceuticals reported an EPS of -€0.294 in its last earnings report, beating expectations of -€0.311. Following the earnings report the stock price went same 0%.

Q: Which hedge fund is a major shareholder of Citius Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:47N0

0 Followers

47N0 Stock Chart & Stats

€3.29

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€3.29

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€3.29 - €3.29

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€13.88M

Enterprise Value€15.28

Total Cash (Recent Filing)€17.01M

Total Debt (Recent Filing)€7.18M

Price to Earnings (P/E)―

Beta-0.06

Next Earnings

Dec 17, 2026

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.11

Shares Outstanding27,452,570

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.20

Price to Sales (P/S)0.00

P/FCF Ratio-0.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.45

Price Target Upside4.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.6

Revenue Forecast (FY)€17.85M

Bulls Say, Bears Say

Bulls Say

Clinical Trials And DataMino-Lok demonstrated an improvement in treatment of CRBSI, achieving its primary endpoint in the P3 study.

Commercialization PotentialCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.

Regulatory ProgressThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.

Bears Say

Financial ConstraintsCitius Pharma reported a net loss with very limited cash, indicating the need to raise capital soon.

Financial PerformanceThe company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.

Regulatory DelaysCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.

Citius Pharmaceuticals News

Citius Pharmaceuticals Receives Nasdaq Extension to Regain Compliance

An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On August 17, 2026, Citius Pharmaceuticals disclosed...

16d ago

CTXR

Is CTXR a Buy, Before Earnings?

Citius Pharma (CTXR) is scheduled to report 3rd quarter earnings on 08/17/2026. Regarding Q3 estimates, Wall Street analysts...

22d ago

CTXR

Citius Oncology reports strong LYMPHIR U.S. launch momentum

Citius Pharmaceuticals ( ($CTXR) ) has issued an update. On August 5, 2026, Citius Oncology reported strong commercial...

1M ago

CTXR

Citius Oncology reports availability of Lymphir in institutions grew 78% in Q3

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), provided an update on the expanding base of...

1M ago

CTOR

CTXR

Citius Oncology provides update on commercial launch of Lymphir

Citius Oncology (CTOR), majority-owned subsidiary of Citius Pharmaceuticals (CTXR), provided an update on the commercial launch of Lymphir...

2M ago

CTOR

CTXR

Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers

Citius Pharmaceuticals ( ($CTXR) ) has shared an announcement. On June 1, 2026, Citius Oncology reported Phase 1...

3M ago

CTXR

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), highlighted Phase 1 clinical data presented May 30...

3M ago

CTOR

CTXR

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX)...

4M ago

AMT

CTMX

Citius Pharmaceuticals files to sell 5.43M shares of common stock for holders

17:02 EDT Citius Pharmaceuticals (CTXR) files to sell 5.43M shares of common stock for holders Published first on...

4M ago

CTXR

Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Citius Pharmaceuticals (CTXR) with a Buy rating and $4 price...

4M ago

CTXR

Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility

Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On May 4, 2026, Citius Pharmaceuticals and its majority-owned...

4M ago

CTXR

Citius Expands LYMPHIR Access with First European Shipment

Citius Pharmaceuticals ( ($CTXR) ) has shared an update. On April 29, 2026, Citius Oncology reported its first...

4M ago

CTXR

Citius Oncology announces initial shipment of LYMPHIR to Europe

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), announced the initial shipment of LYMPHIR to Europe...

4M ago

CTOR

CTXR

Citius Pharmaceuticals Raises $5 Million in Securities Offering

Citius Pharmaceuticals ( ($CTXR) ) has shared an announcement. On April 23, 2026, Citius Pharmaceuticals entered into a...

4M ago

CTXR

47N0 FAQ

What was Citius Pharmaceuticals’s price range in the past 12 months?

Citius Pharmaceuticals lowest stock price was €3.29 and its highest was €3.29 in the past 12 months.

What is Citius Pharmaceuticals’s market cap?

Citius Pharmaceuticals’s market cap is €13.88M.

When is Citius Pharmaceuticals’s upcoming earnings report date?

Citius Pharmaceuticals’s upcoming earnings report date is Dec 17, 2026 which is in 102 days.

How were Citius Pharmaceuticals’s earnings last quarter?

Citius Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -€0.294 earnings per share for the quarter, beating the consensus estimate of -€0.311 by €0.017.

Is Citius Pharmaceuticals overvalued?

According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Citius Pharmaceuticals pay dividends?

Citius Pharmaceuticals does not currently pay dividends.

What is Citius Pharmaceuticals’s EPS estimate?

Citius Pharmaceuticals’s EPS estimate is -0.35.

How many shares outstanding does Citius Pharmaceuticals have?

Citius Pharmaceuticals has 27,452,570 shares outstanding.

What happened to Citius Pharmaceuticals’s price movement after its last earnings report?

Citius Pharmaceuticals reported an EPS of -€0.294 in its last earnings report, beating expectations of -€0.311. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Citius Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:47N0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals (47N0) Earnings & Revenues

Historic Earnings Reports

47N0 Stock 12 Month Forecast

Average Price Target

€3.45

▲(4.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","3":"€3","4":"€4","2.5":"€2.5","3.5":"€3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.4524158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€3.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.4524158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.4524158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,2.5,3,3.5,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.29,3.3024935230769232,3.314987046153846,3.327480569230769,3.3399740923076924,3.352467615384615,3.3649611384615383,3.3774546615384615,3.3899481846153847,3.4024417076923075,3.4149352307692307,3.427428753846154,3.4399222769230766,{"y":3.4524158,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.29,3.3024935230769232,3.314987046153846,3.327480569230769,3.3399740923076924,3.352467615384615,3.3649611384615383,3.3774546615384615,3.3899481846153847,3.4024417076923075,3.4149352307692307,3.427428753846154,3.4399222769230766,{"y":3.4524158,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.29,3.3024935230769232,3.314987046153846,3.327480569230769,3.3399740923076924,3.352467615384615,3.3649611384615383,3.3774546615384615,3.3899481846153847,3.4024417076923075,3.4149352307692307,3.427428753846154,3.4399222769230766,{"y":3.4524158,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >